NCT03070392Phase 2Completed

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2020-10-13Actual

Enrollment · participants378Actual

Source updated2026-03-17Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-03-17 · 1 field changed

Recruitment status changed

− Before

~~Active not recruiting~~

+ After

Completed

Check registry source

Study details

Conditions studied

Uveal Melanoma

Treatments or interventions studied

IMCgp100Biological
DacarbazineDrugAlso known as DTIC-Dome, DTIC, DIC, Imidazole Carboxamide
IpilimumabBiologicalAlso known as Yervoy
PembrolizumabBiologicalAlso known as Keytruda

Primary outcomes · main study measures

measure: Efficacy: Overall Survival; description: Overall survival is defined as the time from randomization to date of death due to any cause.; timeFrame: From randomization to the data cut off date of 13-Oct-2020; median follow-up duration was 14.1 months.

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history